Impact on COVID-19 on cancer diagnosis, treatment & patient mental health

 Insights from Professor Stephen Clarke OAM This week, VIVA! Communications’ Principal, Kirsten Bruce spoke with award-winning Medical Oncologist, Pharmacologist and Translational Researcher, Professor Stephen Clarke OAM, Sydney, about clinical practice during COVID-19, the impact of the virus on cancer diagnosis and treatment, and how cancer patients are faring from a mental health perspective. Although the…

Read More

New combination therapy now reimbursed for Aussies living with incurable blood cancer

Yesterday, VIVA! partnered with Celgene, a Bristol-Myers Squibb company and Myeloma Australia to announce the listing of REVLIMID® (lenalidomide) in combination with bortezomib (Velcade) and dexamethasone (RVd) on the Pharmaceutical Benefits Scheme (PBS). Australians living with the incurable blood cancer, multiple myeloma now have access to this new treatment option. The three drug regimen will…

Read More

Top tips for WFH video calls

How to avoid faux pas & respect your fellow zoomies Working from home presents unique challenges and opportunities for those fortunate enough to be able to do so. Businesses and their employees are doing their best to navigate these unprecedented times, so it’s important to practice patience and respect. Here at VIVA! we are doing…

Read More

Aussies with CVD at higher risk from COVID-19

Tracking the incidence of COVID-19 globally, it is understood that people over the age of 60 with a pre-existing chronic condition, such as cardiovascular disease (CVD) or diabetes, are considered at greater risk to serious infection and complications.1 There has been a high prevalence of CVD in those dying from COVID-19 in Italy and China, two of the worst…

Read More